Investigational cytology test is designed to help clinicians assess suspicious oral lesions with a quantitative index.
OraLiva, Inc., an early cancer detection company developing AI-enabled cytology diagnostics, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ORAL ONC-InCYT, an investigational test designed to help clinicians assess suspicious white or red oral lesions.
ORAL ONC-InCYT analyzes cells collected from a lesion with a brush, evaluating cellular morphology and biomarker-related features to generate a quantitative Oral Cancer Numerical Index (OCNI). The OCNI is designed to be interpreted alongside a clinician’s overall evaluation to support decisions such as specialist referral, biopsy, or escalation of care. The designation covers use in adults with lesions suspected to represent an oral potentially malignant disorder or an oral lichenoid condition.
More than 60,000 Americans will be diagnosed with oral cavity or oropharyngeal cancer in 2026, and more than 13,000 will die from it, according to the American Cancer Society. Too many cases are still caught late, often after a lesion has been monitored for months because clinicians have lacked objective tools to help determine which lesions warrant escalation.
The FDA’s Breakthrough Devices Program is intended for medical devices that may provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions. Designated devices are eligible for prioritized interaction with FDA experts during development and prioritized review of marketing submissions, with the goal of getting important innovations to patients sooner.
“Cancer is, at its core, a disease of cellular dysregulation, so the cells collected from a suspicious lesion carry some of the most direct evidence of what is happening in that tissue,” said John T. McDevitt, Ph.D., Chief Scientist at OraLiva. “ORAL ONC-InCYT is designed to capture those cellular signatures, combining cell morphology and biomarker-related features with deep learning to produce a quantitative index. We see cytosignatures as a distinct class of biomarker, complementary to the nucleic acid, protein, and microbiome approaches the field has pursued for years, where reaching robust clinical validation has proven difficult. FDA brings rigor to that challenge, and Breakthrough Device Designation gives us a framework to work closely with the agency as we generate the clinical evidence needed to support marketing authorization.”
OraLiva’s deep-learning cytology platform powers a portfolio of oral lesion tests available today to dentists and specialists as laboratory-developed tests (LDTs), performed in the company’s CLIA-certified laboratory in Durham, N.C. OraLiva began offering its LDTs in spring 2026. With Breakthrough Device Designation, OraLiva will work closely with the FDA as it pursues marketing authorization for ORAL ONC-InCYT.
“Clinicians are already using our laboratory tests to help evaluate suspicious oral lesions,” said Spencer Price, CEO of OraLiva. “Pursuing FDA marketing authorization for ORAL ONC-InCYT is how we aim to make this kind of cytology-based assessment available more broadly, and Breakthrough Device Designation lets us work closely with the agency as we do it.”
Beyond oral lesions, OraLiva is exploring applications of its AI-enabled cytology platform in other epithelial cancers.
ORAL ONC-InCYT is an investigational device, is not available for clinical use, and has not been cleared, approved, or otherwise authorized by the FDA. OraLiva’s laboratory-developed tests are performed under CLIA, have not been cleared, approved, or otherwise authorized by the FDA, and are not covered by the Breakthrough Device Designation. Breakthrough Device Designation does not change the FDA’s requirements for marketing authorization or guarantee that authorization will be granted.
OraLiva is empowering providers with tools for the future of early cancer detection. Its AI-enabled cytology laboratory-developed tests analyze simple, minimally invasive brush samples to generate a quantitative index that helps dentists and specialists evaluate suspicious oral lesions.
OraLiva’s mission is to make early cancer detection possible at every level of care.
Source: https://www.oraliva.com/
News 11 May 2026
Food and Drug Administration (FDA) has granted FDA clearance for its Dx Software following a review completed on April 10, 2026.
Products 22 December 2025
AI dental company announces 510(k) clearance from the U.S. Food and Drug Administration for Overjet CBCT Assist.
News 05 November 2025
Perimetrics, Inc., a dental technology company pioneering quantitative diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for the InnerView...
Products 26 November 2024
DentalMonitoring Enhances Orthodontic Software With FDA-Cleared AI Technology
DentalMonitoring, the leader in artificial intelligence (AI)-powered remote monitoring for orthodontics, has released a major software update introducing features and indications based on the...
News 15 October 2024
Relu Secures FDA Clearance and CE Mark Approval for Revolutionary Dental AI Tool
Relu, a pioneer in artificial intelligence (AI)-assisted segmentation for dental labs and software companies, proudly announces the dual achievement of 510(k) clearance by the U.S. Food and Drug...
News 19 November 2026
The Delta Dental Community Care Foundation, the philanthropic arm of Delta Dental of California and its affiliates, announced $16.3 million in Access to Care Grant funding, continu
News 19 November 2026
Henry Schein Announces Upcoming Investor Conference Presentations
(Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the followin
Editorials 19 November 2026
Twenty Florida high school students recently visited the UF College of Dentistry, or UFCD, for a day of programming designed to help them explore potential careers in dentistry.
Periodontology 19 November 2026
This peer-reviewed periodontology article summarizes clinical evidence from Journal of periodontology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions,...
Products 18 November 2026